NasdaqGS · Biotechnology

Immunovant (IMVT)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+10.2%

$48.88 average target

$44.37+0.02 (+0.0%)Latest market snapshot · Yahoo Finance

Market cap$9.16B

Cash$797.8M

Quarterly burn$124.4M

Pipeline assets12

Short float17.8%

Market context

IMVT Stock Chart

Loading interactive chart…

Chart provided by TradingView. Market data may be delayed.

Next catalyst

Batoclimab (IMVT-1401)

TBA · Discontinued

View pipeline & catalysts

Company profile

About Immunovant

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.